ArticleProstate cancer and prostatic diseases2025

A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis.

Osama Mosalem et al.PubMed ↗Publisher ↗

No numbers read from the abstract.